SAEs (4%, 95% CI: 1%-9%) and discontinuations (3%, 95% CI: 1%-7%) were uncommon.<h4>Conclusion</h4>Calcitonin gene-related peptide antagonists provide preventive benefit with acceptable safety in cluster headache. This evidence concerns the gene CALCA and Cluster headache.